Cell Reports Medicine · 2024 · 23 citations · 30 references
Life SciencesMolecular BiologyOncologyApoptosisDna RepairMolecular OncologyApoptosis In CancerApoptosis ResistanceCrispr-cas SystemsDna Damage SignalingDna Damage-induced ApoptosisTumor Suppressor GenesCrispr-cas9 KnockoutDna Double-strand BreaksG2/m TransitionKinase InhibitorsKras G12c InhibitionNon-small Cell Lung Cancer TreatmentWee1 InhibitionWee1 Kinase Inhibition
The clinical development of Kirsten rat sarcoma virus (KRAS)-G12C inhibitors for the treatment of KRAS-mutant lung cancer is limited by the presence of co-mutations, intrinsic resistance, and the emergence of acquired resistance. Therefore, innovative strategies for enhancing apoptosis in KRAS-mutated non-small cell lung cancer (NSCLC) are urgently needed. Through CRISPR-Cas9 knockout screening using a library of 746 crRNAs and drug screening with a custom library of 432 compounds, we discover that WEE1 kinase inhibitors are potent enhancers of apoptosis, particularly in KRAS-mutant NSCLC cells harboring TP53 mutations. Mechanistically, WEE1 inhibition promotes G2/M transition and reduces checkpoint kinase 2 (CHK2) and Rad51 expression in the DNA damage response (DDR) pathway, which is associated with apoptosis and the repair of DNA double-strand breaks, leading to mitotic catastrophe. Notably, the combined inhibition of KRAS-G12C and WEE1 consistently suppresses tumor growth. Our results suggest targeting WEE1 as a promising therapeutic strategy for KRAS-mutated NSCLC with TP53 mutations.
30
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Raffaella Di Micco, Marzia Fumagalli, Angelo Cicalese et al. · Nature · 2006 · 1.8K citations
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao et al. · Cancer Discovery · 2015 · 916 citations · Full text
Medicine, Immunology, Oncology +17